Access to cancer drugs in Australia is coming to a head after a bitter tit for tat over a pharma push to fast-track oncology treatment. The industry is calling for a more flexible and fast-tracked approach to approving new cancer drugs, claiming the current system is outdated. Australia ranks 18th out of 20 comparable OECD … Continued
New studies which show that patients in some countries can wait years longer than those in others to access potentially life-saving cancer drugs demonstrate the need for better collaboration between doctors and health authorities globally, say researchers. A comparison of approval times for 41 cancer drugs in Canada, the US and the European Union found … Continued
Sign up to receive updates from GAfPA
Biosimilar Briefings Review Nature and Impact of Biosimilars on Access
October 1, 2019
What New Cholesterol Guidelines Mean for Patients
September 27, 2019